Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15280838 | 0.86 | CYP2C9 (0.57) | GRM3CYP2C9CYP2C19FOLH1 | |
| SCHEMBL14927202 | 0.86 | CYP2C9 (0.60) | GRM3CYP2C9CYP2C19FOLH1 | |
| SCHEMBL8056003 | 0.80 | FOLH1 (0.67) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1373664 | 0.78 | GRM3 (0.65) | GRM3FOLH1 | |
| SCHEMBL11134968 | 0.77 | CPA3 (0.57) | CYP2C19FOLH1 | |
| SCHEMBL5052894 | 0.77 | CPA3 (0.71) | GRM3FOLH1 | |
| SCHEMBL12145183 | 0.77 | GRM3 (0.68) | GRM3FOLH1 | |
| SCHEMBL4135913 | 0.77 | GRM3 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5053123 | 0.76 | FOLH1 (0.61) | GRM3FOLH1 | |
| SCHEMBL8468631 | 0.76 | GRM3 (0.66) | GRM3FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | PFIZER INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3511019-B1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-2774608-B1 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190269617-A1 | Methods of Controlling Morphology of Polymeric Nanoparticles | PFIZER INC. (US) | 2019-09-05 | — | — | US | disclosed |
| EP-3511019-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3116547-B1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190111004-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190091164-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | PFIZER INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-8246968-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8236330-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8206747-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2011-09-15 | — | — | US | disclosed |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | GRM3 3796/4885CYP2C9 2956/4885CYP2C19 3149/4885 |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | GRM3 3576/4885CYP2C9 4468/4885CYP2C19 4474/4885 |
| US-20190111004-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CD44, NCL, TP53 | GRM3 2403/4885CYP2C9 4841/4885CYP2C19 4836/4885 |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | GRM3 3970/4885CYP2C9 2458/4885CYP2C19 2844/4885 |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | GRM3 3576/4885CYP2C9 4468/4885CYP2C19 4474/4885 |
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | CD47, CD274, PDCD1 | GRM3 1415/4885CYP2C9 4835/4885CYP2C19 4738/4885 |
| US-20190269617-A1 | Methods of Controlling Morphology of Polymeric Nanoparticles | CLTB, NCL, ACTB | GRM3 3686/4885CYP2C9 4820/4885CYP2C19 4761/4885 |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | CTSA, GAA, EEA1 | GRM3 3516/4885CYP2C9 4878/4885CYP2C19 4872/4885 |
| US-20190091164-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same | CTSA, GAA, EEA1 | GRM3 3516/4885CYP2C9 4878/4885CYP2C19 4872/4885 |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | GRM3 3406/4885CYP2C9 3670/4885CYP2C19 4110/4885 |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | GRM3 3796/4885CYP2C9 2956/4885CYP2C19 3149/4885 |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | GRM3 3576/4885CYP2C9 4468/4885CYP2C19 4474/4885 |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | LPXN, LIPA, CHMP4B | GRM3 2491/4885CYP2C9 3489/4885CYP2C19 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.